Regan M. Memmott
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
73
Citations
2,204
Est. group size
~32
Recurring co-author estimate
Active years
26
Publishing since 2001
Regan M. Memmott's research focuses on lung cancer biology and treatment, examining how metabolic factors like diet, diabetes drugs (metformin), and growth-factor signaling (such as IGF-1 and mTOR/PI3K/AKT pathways) influence lung tumor development. The work spans laboratory studies in mouse models of lung cancer as well as clinical trials testing targeted drugs (such as EGFR inhibitors, sirolimus, and metformin) in patients with non-small cell lung cancer (NSCLC).
Publication output was sparse and irregular through the late 2010s, then rose sharply in 2023 with a large cluster of related outputs, and has remained comparatively active through 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
Journal of Clinical Oncology · 2026
- Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
Journal of Clinical Oncology · 2025
- Data from Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling
2023
- Data from Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
2023
- Data from Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
2023
- Supplementary Figure Legend from Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling
2023
- Supplementary Figures 1 - 5 from Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling
2023
- Related Articles / Press Coverage from Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
2023
- Supplementary Figures 1 and 2 from Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
2023
- Supplementary Figure Legend from Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling
2023
- Supplementary Figures 1 and 2 from Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
2023
- Supplementary Figures 1 - 5 from Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling
2023
- Related Articles / Press Coverage from Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
2023
- Data from Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling
2023
- A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in <i>PTEN</i>
The Oncologist · 2019
- Journal of Clinical Oncology×12
- Journal of Thoracic Oncology×6
- Journal of the National Comprehensive Cancer Network×4
- Cancer Research×4
- Regular and Young Investigator Award Abstracts×2
- Dasheng Wang
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Frederick Nguele Meke
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Cho-Hao Lin
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Darien E. Reed
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Jinan Ayub
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile